Hilton, John

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 743

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Hilton, J., Gelmon, K., Bedard, P. L., Tu, D., Xu, H., Tinker, A. V., Goodwin, R., Laurie, S. A., Jonker, D., Hansen, A. R., et al. (2022) · Nature Communications

DNA and Nucleic Acid ChemistryPARP inhibition in cancer therapy

Cited by 155

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer

Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 27